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Abstract 
HIV-associated cryptococcal meningitis is by far the commonest cause of adult 
meningitis in many areas of the world with high HIV seroprevalence, and in most 
centres in Sub-Saharan Africa cases are not decreasing despite availability of 
antiretroviral therapy because of the challenges of retention in care and adherence. In 
addition, non HIV-associated cryptococcal meningitis is a significant problem in 
transplant recipients and others with defects in cell-mediated immunity, and in the 
apparently immunocompetent - with high mortality rates in these groups, despite 
therapy. Recent advances have been made in rapid point-of-care diagnosis, and early 
detection of cryptococcal antigen in blood has enabled the development of a screen 
and pre-emptive treatment strategy to prevent the development of clinical infection in 
late stage HIV-infected patients. Progress in optimising antifungal combinations has 
been aided by evaluation of rate of clearance of infection derived from serial 
quantitative cultures of cerebrospinal fluid (CSF). Measurement and management of 
raised CSF pressure, a common complication, is a vital component of care. In 
addition, there is an improved understanding of protective immune responses in HIV-
associated cases, immune-genetic pre-disposition to infection in non HIV-infected 
patients, and the role of immune-mediated pathology – in non HIV-infected patients, 
as well as in the context of HIV-associated immune reconstitution reactions.  
 
Key Points 
HIV-associated cryptococcal cases in most centres in Africa are not decreasing 
despite access to antiretrovirals due to challenges with retention in care and 
adherence. 
 
Non-HIV-associated cryptococcal meningitis, although relatively rare needs to be 
considered in all cases of lymphocytic meningitis, even in the apparently 
immunocompetent, and carries a mortality at least as high as HIV-associated disease. 
 
A point-of-care lateral flow “dipstick” test to detect cryptococcal antigen in blood or 
CSF is highly specific and a significant advance in terms of sensitivity as well as ease 
of use in the diagnosis of cryptococcal disease. 
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Amphotericin B, in conventional or liposomal formulation, plus flucytosine remains 
the induction therapy of choice and is associated with a survival advantage over 
amphotericin B alone.  
 
Measurement of CSF opening pressure and appropriate management of raised CSF 
pressure is associated with reduced mortality 
 
Any future attempts at adjunctive immunotherapies will need to be closely guided by 
the specific immune status, and/or defect, of the host at the time of any intervention.   
 
 
Introduction: 
 
Cryptococcal meningitis (CM) is the commonest cause of adult meningitis in large 
parts of the world with high rates of HIV infection [3-5]. In addition, it occurs in an 
increasing number of patients with other forms of natural and iatrogenic 
immunosuppression, and in the apparently immunocompetent, particularly in the Far 
East [6]. In the U.S., deaths from non-HIV-related CM now account for 
approximately a quarter of CM-related hospitalizations and a third of deaths [9]. 
Furthermore, an outbreak of cryptococcal disease in Pacific Northwest North America 
caused by a novel lineage [10], highlights the threat posed by Cryptococcus sp [see 
BOX, [12]]. Cryptococcus sp are currently the only significant human fungal 
pathogens from the large group of basidiomycete fungi, but they share some of the 
properties - high virulence, generalist pathogens, with long-lived environmental 
stages, and the potential for wide dispersal and rapid evolutionary change, that have 
made fungal organisms in general such a growing threat not only to human, but also 
to animal and plant health [14].   
 
Herein, we review recent advances in the epidemiology, diagnosis, and clinical 
management of cryptococcal meningitis, including the optimisation of antifungal 
therapy and the management of neurological complications. We discuss patient and 
situation specific adjunctive immuno-suppressive or -augmenting therapies – based on 
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advances in our understanding of susceptibility to infection, immunopathological 
mechanisms, and protective immune responses, in specific patient groups; and 
strategies for the prevention of HIV-associated cases through screening for sub-
clinical infection and pre-emptive therapy.  
 
Epidemiology 
 
HIV-associated Disease 
 
In a landmark 2009 study, the CDC estimated the global burden of HIV-associated 
cryptococcal meningitis, based on available incidence data within HIV-infected 
cohorts in different regions. They estimated that there were close to one million cases 
per year, with at least 100,000 and perhaps 500,000 deaths per year in Sub-Saharan 
Africa alone [18]. Other data suggesting that in some populations 10-15% of AIDS 
deaths (which peaked at 2.3 million per year in 2005 according WHO figures) are due 
to cryptococcal disease [19], also put the number of deaths in the hundreds of 
thousands. An updated analysis by Boulware and colleagues, including the CDC 
group, has used a different approach, based on the number of patients at risk, with 
CD4 cell counts <100 and not on effective antiretroviral therapy (ART), and the 
prevalence of cryptococcal antigenaemia and risk of progression. This still puts the 
number of deaths at 180,000 per year, 132,000 in Africa, and accounting for 17% of 
AIDS mortality [Boulware DR, et al. Update on the Global Burden of Disease of 
HIV-Associated Cryptococcal Meningitis. Oral Abstract presented at: 9th 
International Conference on Cryptococcus and Cryptococcosis; 2014 May; 
Amsterdam] 
 
In Europe and North America the numbers of cryptococcal cases fell dramatically 
after introduction of effective ART, with hospitalizations in one US study falling by 
half [9]; and in South Africa, where surveillance has been carried out since the early 
2000s, there has been a modest reduction in cases from a peak between 2005 and 
2009 [http://www.nicd.ac.za/assets/files/GERMS-SA%20AR%202014.pdf, p8-11]. 
But importantly, there is as yet no evidence of a decrease in cases in many high 
incidence African countries despite increased access to ART [20]. In Botswana, 
despite a relatively well-resourced and functioning ART programme, nationwide 
5 
 
surveillance shows that the numbers of cryptococcal cases have actually increased 
since 2011, likely driven by the numbers of patients defaulting from care [Tenforde et 
al. HIV-associated cryptococcal meningitis in Botswana: national incidence and 
temporal trends following ART rollout. IAS Meeting Durban 2016, Abtract 
WEPEB036]. Thus, while total numbers of cases are static, in many centres half of all 
patients are now presenting having been prescribed ART, but with persisting low CD4 
cell counts due to loss to follow up, non-adherence, and/or the development of ART 
resistance [unpublished enrolment data ACTA trial, ISRCTN 45035509; [21, 22].  
 
Predisposition to infection in non-HIV-infected individuals 
 
The numbers of HIV-associated cases dwarf those in non-HIV infected populations in 
many low and middle income countries. Nevertheless, cryptococcal meningitis is a 
significant problem in transplant recipients and other patients with defects in cell-
mediated immunity, with high rates of death despite therapy [9]. In a series of over 
300 HIV-negative patients with cryptococcal infection from the USA, half had CNS 
involvement and of these, 25% had had steroid therapy, 24% chronic liver, kidney or 
lung disease, 16% malignancy, and 15% solid organ transplants [23]. Hematopoietic 
malignancies are associated although stem cell transplant patients are typically not at 
increased risk because of widespread use of azole prophylaxis in this population. In 
addition, there is a well-recognised but poorly understood association with 
sarcoidosis, as well as other autoimmune diseases such as ankylosing spondylitis, 
dermatomyositis, SLE, and autoimmune hepatitis, although some of these 
associations could be due to steroid therapy [24]. Interestingly, even in the developed 
world, mycobacterial disease is an associated co-morbidity [9], which could be due to 
a common susceptibility to these two intracellular pathogens as this relationship is 
seen in HIV-related cases as well [25]. Of note, in the USA series, 30% had no 
apparent underlying condition. C. neoformans cases occur in apparently 
immunocompetent patients across the world, with large numbers reported in the Far 
East [6]. In addition meningitis caused by C. gattii, occurs throughout the tropics, 
including Australasia [26] and South America, in apparently immunocompetent 
patients, and notably in the outbreak in Pacific Northwest of North America [10]. 
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CM in previously healthy individuals is a relatively rare disease, with approximately 
3000 cases annually in the U.S, thus affecting approximately 1 in 100,000 individuals 
per year. This incidence suggests that these apparently ‘normal hosts’, may actually 
harbour rare primary immune defects or uncommon autoimmune diseases. As shown 
in Table 1, a number of immune deficiencies have been associated with cryptococcal 
meningitis. Idiopathic CD4 lymphopenia (ICL) is the best known risk factor, defined 
as the repeated presence of a CD4+ T-lymphocyte count of fewer than 300 cells per 
cubic millimetre without a predisposing cause. In a recent meta-analysis of ICL cases, 
cryptococcosis was the most common infection seen, in 27% of reported cases [27]. 
ICL is a heterogeneous disease of unknown cause, although several monogenic 
mutations have been reported including a recent association of defects in T-cell 
receptor signalling and a mutation in the UNC119 gene [28]. Autoantibodies to 
granulocyte-macrophage colony stimulating factor (GMCSF) and its associated 
syndrome, pulmonary alveolar proteinosis has been associated with intracellular 
infections including Cryptococcus [29]. More recently, the antibody has been 
characterized as a functional antibody blocking STAT5 phosphorylation involved in 
macrophage signalling, and has been found in patients with C. gattii infection in the 
Pacific northwest [30, 31]. Autoantibodies against IFN- have also been associated 
with cryptococcal disease [32]. In addition, cryptococcal disease has been associated 
with syndromes caused by monogenic mutations including an autosomal dominant 
and sporadic monocytopenia caused by mutations in GATA2 zinc finger transcription 
factor essential for lymphatic angiogenesis [33-35], hyperimmunoglobulin E-
recurrent infection (Job’s) syndrome, caused by mutations in the signal transducer and 
activator of transcription, STAT3 [36, 37], as well as X-linked hyper-IgM 
immunodeficiency associated with a number of mutations [38, 39]. In addition, while 
CM in previously healthy patients is a rare disease, common genetic polymorphisms 
have been associated with disease in this population such as FCy receptor IIB 
polymorphisms and could represent disease modifier genes [40]. 
   
Outcomes and Prognostic factors  
 
Outcomes for patients with HIV-associated cryptococcal meningitis in Africa remain 
poor, with overall best estimates suggesting a 70% 3 month mortality, driven by late 
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presentation, and lack of access to drugs, manometers, and optimal monitoring. 
Fluconazole therapy is associated with 10-week mortality of 50-60% in prospective 
research studies [41-43]. Amphotericin B-based treatment, in trial settings, is still 
associated with 10-week mortalities of 24-42% [21, 44-46]. In resource rich settings, 
studies from the USA and France suggest that 10-week mortality is still between 15 
and 26%, and has not changed since the availability of ART [47-49]. In a US study, 
90 day mortality for non-HIV infected patients was 27%, higher than for HIV-
infected [50], which may be due to both delays in diagnosis and associated immune 
dysregulations [51]. In non-HIV-infected individuals, C. gattii tends to cause more 
granulomatous lesions in both lung and brain with more neurological sequelae [10, 
52, 53], although in the context of HIV-infection, the presentation and outcomes of C. 
gattii and C. neoformans infections are not readily distinguishable [54].   
 
A recent analysis of over 500 patients, confirmed and extended our understanding of 
the factors in HIV-related cryptococcal meningitis associated with poor outcome: 
above all, altered mental status at presentation, and baseline fungal burden (assessed 
by colony forming unit (CFU) count), and also, older age, and low weight [55]. In 
addition, the rate of clearance of infection, dependent on antifungal therapy and host 
immune response, is independently associated with outcome [55, 56], making this a 
clinically relevant endpoint for phase 2 studies of novel antifungal regimens (see 
below).  
 
In non-HIV cases, in addition to altered mental status and fungal burden, markers of a 
poor inflammatory response, low CSF white cell count, and absence of headache, and 
underlying haematological malignancy and chronic renal and liver disease have been 
linked with poor prognosis [23, 53, 57, 58].  
 
Protective immune responses in HIV-infected patients  
 
Jarvis et al have carried out detailed analyses of local and systemic immune responses 
in patients with HIV-associated cryptococcal meningitis, at baseline and over time on 
treatment, from cytokine and chemokine profiling of CSF, and from determination of 
the pattern of intracellular cytokine production by CD4 memory cells when peripheral 
blood mononuclear cells (PBMC) are stimulated ex vivo with cryptococcal 
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mannoproteins [59, 60]. Linkage of immune response data to clinical parameters and 
outcomes allows an investigation of responses associated with survival. Variation in 
CSF parameters at baseline could be largely explained by 2 principal components. 
PC-1 was driven by higher levels of IL-6 and IFN-, and also IL-8, IL-10, RANTES, 
TNF-, and IL-17. Consistent with prior work [61] this pro-inflammatory response 
was correlated with higher peripheral CD4 cell and CSF white cell counts, markers of 
CSF macrophage activation, lower fungal burden, more rapid clearance of infection, 
and survival [60] (Figure 1A). Analysis of systemic responses showed a similar 
pattern – patients who survived had a significantly higher proportion of CD4 memory 
cells producing IFN- and TNF- and polyfunctional cells producing both cytokines, 
than patients who died, whose cryptococcal-specific CD4 memory cells were 
dominated by cells producing only MIP-1[60] 2he results are 
consistent with recent independent work relating poor survival to decreased monocyte 
production of TNF-; and reduced IFN- responses in whole blood stimulated with 
LPS [62].   
 
 
Clinical features, pathology, and radiology 
 
Cryptococcal meningitis is a sub-acute meningo-encephalitis. The organism is 
acquired by inhalation, but can then disseminate, probably in many cases after a latent 
period contained within lung lymph nodes [63]. Whilst involvement of almost all 
organs and tissues has been reported, there is a very significant predilection for the 
CNS. This strong neurotropism has been linked to a number of cryptococcal-specific 
virulence factors that facilitate penetration of the blood brain barrier such as specific 
metalloproteinases and ureases; enzymes that cause neuro-immunomodulation such as 
a dopamine-utilizing laccase; and mechanisms that facilitate survival within the 
nutrient deprived environment of the brain such as autophagy and high affinity sugar 
transporters (reviewed in [64]). 
 
Thus, patients present with neurologic symptoms of headache and mental status 
changes as well as fever, nausea and vomiting, with a median duration in HIV-
associated cases of 2 weeks and 6-12 weeks in non-HIV cases. Many will develop 
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visual symptoms, of diplopia and then reduced acuity secondary to high CSF pressure 
(see below), and /or involvement of the optic nerve and tracts [65]. Without treatment, 
patients progress with confusion, seizures, reduced conscious level, and finally coma. 
Many cases may also have concomitant lung involvement, although in HIV-
associated CM, this may often be overlooked, or misdiagnosed as TB [66]. Indeed in 
HIV-infected patients, while meningo-encephalitis dominates the clinical 
presentation, disseminated infection is probably common. In non-HIV-infected 
patients, presentations may be determined as much by host immune responses as by 
fungal species/lineage differences, and exhibit marked heterogeneity. For example, 
organ transplant recipients undergoing intensive conditioning may have more acute 
presentations with limited inflammatory sequelae or may present with an IRIS-like 
picture after reductions of immunosuppression [67]. Previously healthy non-HIV 
infected patients infected with either C. neoformans or C. gattii present with a more 
chronic course often without fevers that delays diagnosis. Inflammatory sequelae, 
including hydrocephalus, may be present at diagnosis or occur during therapy and are 
reported more frequently with C. gattii [52], perhaps due to induction of higher 
concentrations of pro-inflammatory cytokines [68].  
 
In autopsy series, HIV-associated CM is characterised by many predominantly 
extracellular organisms, throughout the parenchyma and meninges, sometimes in 
grossly visible accumulations, with little inflammatory response [69]. In non-HIV 
cases, there are fewer organisms, largely confined to the meninges and large 
perivascular Virchow-Robin spaces, associated with a diverse inflammatory response 
ranging from granulomatous to a more disorganized macrophage infiltration [69, 70]. 
Immunohistochemistry studies also demonstrate cryptococcal capsule polysaccharide 
throughout the brain, localized in macrophages and microglia, especially in HIV-
associated cases [71].  
 
Many of these pathological features can be seen on brain MRI scans, including dilated 
Virchow-Robin spaces, pseudocysts, cryptococcomas, and cortical and lacunar 
infarcts [72, 73].  In HIV-negative cases, a larger proportion of patients have large 
space-occupying cryptococcomas with a marked surrounding inflammatory response, 
and hydrocephalus.  
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Diagnosis 
 
Characteristic CSF parameters are a raised white cell count, with lymphocyte 
predominance, elevated CSF protein, and low CSF glucose. In HIV-associated 
cryptococcal meningitis, the CSF white cell count is lower (median 15 x 106/L [55]) 
and frequently normal. Diagnosis should not be an issue in HIV-associated 
cryptococcal meningitis, given the high fungal burden. Simple India Ink examination 
of CSF has a sensitivity in the order of 70-90% and cases that are India Ink negative 
will be reliably diagnosed by detection of cryptococcal antigen 
(glucuronoxylomannan, the dominant capsular polysaccharide) and culture. However, 
until recently, antigen detection was based on latex agglutination tests, which though 
sensitive and specific, were never widely available in high burden, resource-limited 
settings. In this context, development of a lateral flow assay (LFA) has been a major 
advance. The test meets the ASSURED (Affordable, Sensitive, Specific, User-
friendly, Rapid/Robust, Equipment-free, Delivered) criteria [74] for point-of-care 
tests, has a 2-year shelf life at room temperature and requires no specimen 
preparation. In addition, it is in the order of 100-fold more sensitive in ng/ml of 
polysaccharide detected, than the older latex agglutination tests, across the 4 
cryptococcal serotypes [75, 76]. Availability of this test makes the screen and pre-
emptive therapy prevention strategy, discussed below, feasible. It also enables earlier 
diagnosis prior to lumbar puncture, through testing of serum, plasma, or whole blood 
finger prick samples [77], in primary care settings, and through screening of medical 
in-patients in high incidence areas. Urine samples although containing antigen, are 
prone to false positive results with the current test [78, 79]. More studies are needed, 
however, to demonstrate better outcomes through earlier, LFA-based diagnosis. A 
second, semi-quantitative, lateral flow test is now in development by Biosynex in 
collaboration with Francoise Dromer at Institut Pasteur [www.biosynex.com/fr/test-
cryptops/], with two positive bands giving a high or low level antigen result, which 
may prove useful in individualising treatment, based on fungal burden, especially in 
the setting of screening.   
 
Fungal burden may be much lower in some cases of HIV-associated unmasking 
cryptococcal meningitis, presenting after initiation of antiretroviral therapy, in which 
immune reconstitution may play a more dominant role than active infection (see 
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below). In these cases, CSF cultures may be negative. Similarly, in HIV-negative 
cryptococcal meningitis, cultures and latex agglutination tests, especially for C. gattii 
infections, may be negative and repeat large volume CSF samples have sometimes 
been required in the past [80]. In these settings, the greater sensitivity of the new LFA 
test for both species is a major advantage [81, 82], and means the diagnosis of 
cryptococcal meningitis should not be delayed so long as the diagnosis is considered 
in all patients with a lymphocytic meningitis, even those who are apparently 
immunocompetent. 
 
 
Antifungal therapy  
 
Current recommendations for first-line antifungal treatment have not changed 
significantly for a decade [83-85] (Table 2), and are based on an induction, 
consolidation and then maintenance therapy approach first used in the landmark 1997 
Mycoses Study Group trial [86], and subsequent studies showing that Amphotericin B 
plus flucytosine led to the most rapid clearance of infection [87], and, more recently, 
that demonstrated a survival benefit with this combination over amphotericin alone 
[88]. In fact, the latter study found a reduction of almost 40% in the relative risk of 
death at 10 weeks with addition of flucytosine. Of note, flucytosine at currently used 
dosage, for 2 weeks in HIV-associated CM, with monitoring of FBC, rather than 
serum levels, has been found to be well-tolerated, [88-90]; and in PK/PD studies in 
patients, levels usually associated with bone marrow suppression were not found [91]. 
Care must be taken, however, to adjust the dose if renal impairment secondary to 
amphotericin develops. 
 
Importantly however, Amphotericin B deoxycholate (D-AmB) is associated with 
renal impairment, hypokalaemia and hypomagnesaemia, and anaemia, especially 
during the second week of induction therapy [90]. Saline and fluid loading equivalent 
to 1L Normal saline, in addition to usual fluid requirements, has been shown to 
reduce renal impairment [92, 93], and potassium and magnesium supplements are 
recommended, with careful monitoring [83]. In a recent combined cohort, the average 
fall in haemoglobin with 14 days D-AmB, was 2.3 g/dl [90], which is challenging in 
centres where transfusion capacity is limited. Liposomal amphotericin B (L-AmB) is 
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equally effective and better tolerated [94]. Optimal dosing and schedules are still not 
defined, and it may be that one or few large intermittent doses together with oral 
therapy, could provide a safe and effective induction regimen, which would be more 
cost-effective and sustainable in resource limited settings compared with current daily 
dosing. This approach is being tested in the ongoing Ambition-CM trial [95]. 
 
The rate of clearance of infection derived from quantitative cultures of CSF from 
serial lumbar punctures over the first 2 weeks of treatment provides a statistically 
powerful and clinically relevant endpoint to explore the activity of new dosages and 
drug combinations. Such early fungicidal activity (EFA) studies have influenced 
recommendations where resources are limited. Higher doses of fluconazole, up to 
1200 mg/d, are more fungicidal than previously used lower doses and safe [43], and 
the combination of high dose fluconazole plus flucytosine has an EFA that 
approaches that measured for amphotericin B alone [96]. This oral combination may 
also prevent emergence of secondary fluconazole resistance . In addition shorter, 7-
day induction with D-AmB does not appear to lead to reduced EFA, perhaps due to 
the prolonged half-life of D-AmB in brain tissues, and is much better tolerated [97-
99]. Based on these phase II studies, high dose fluconazole plus flucytosine and one 
week D-AmB-based induction are being compared against the standard of 2 weeks of 
D-AmB-based therapy in African centres in the phase III ACTA trial that will report 
next year (ISRCTN 45035509). Both these new regimens, if as effective as 2 weeks 
D-AmB, would be much more readily and safely sustained in resource-limited 
settings than 2 weeks D-AmB.  
 
EFA has also been used to explore the in vivo efficacy of established drugs, known 
from pre-clinical studies to have anticryptococcal activity, for possible repurposing 
for cryptococcal meningitis. Addition of sertraline to AmB plus fluconazole was 
associated with an increase in EFA in a Ugandan cohort, compared with historical 
controls treated without sertraline at the same centre [22], and is being tested now in 
phase III (results expected in 2018); and there are other candidate agents, suitable for 
similar testing [100]. At least one new agent, Viamet 1129, is being developed 
specifically for cryptococcal meningitis. It is a novel oral azole-like compound that is 
concentrated in brain tissue and shows impressive cidal activity in animal models 
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[http://www.viamet.com/pipeline/vt-1129.php]. Phase I studies have started, with 
phase II EFA studies under development.  
 
In non-HIV infected patients, clinical response is as much about controlling immune 
dysregulation as in microbiological control. Initial therapy with Amphotericin B and 
flucytosine is similar to that for HIV-related disease, but induction is for 4-6 weeks 
[10, 84, 101](Table 2) and lipid formulations have been favoured over the 
deoxycholate preparation because of reduced renal toxicity. Previously healthy 
individuals patients with idiopathic CD4 lymphopenia may take longer to respond 
microbiologically, but have less immune sequelae; whereas those with normal CD4 
counts may have immune sequelae on presentation or, in a significant minority, such 
sequelae may develop despite microbiological control (discussed below). 
 
Reduction of immunosuppression in solid organ transplant recipients is an intuitively 
logical approach after severe infections such as cryptococcosis and is well tolerated. 
However, discontinuation of agents such as calcineurin agents has been associated 
with clinical deterioration and IRIS, although discontinuation of corticosteroids was 
not (Sun HY, Forrest G, Alexander BD, et al. Predictors of immune reconstitution syndrome (IRS) in 
transplant recipients with cryptocococcosis [abstract #M-1138]. Interscience Conference on 
Antimicrobial Agents and Chemotherapy, Chicago IL, September 17–20, 2011.), [102]. 
Calcineurin inhibitors have an added benefit of being synergistic with antifungals 
against Cryptococcus and have been associated with better outcomes in post-
transplant cryptococcosis [103].  
 
Raised CSF pressure 
 
Half of HIV-infected patients with cryptococcal meningitis have a CSF opening 
pressure of >25 cm and roughly a quarter >35 cm [55, 104]. High pressures are 
associated with worse symptoms, of headache, nausea, diplopia secondary to 6th nerve 
palsies, and finally altered mental status. Head scans show that hydrocephalus is rare 
in HIV-associated meningitis [72], and the pathophysiology is most likely due to 
blockage of CSF reabsorption by organisms, alive or dead, and /or shed cryptococcal 
polysaccharide at the level of the arachnoid granulations and elsewhere [105]. In a 
small post mortem series arachnoid granulation tissue contained many fungal cells, in 
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comparison with the rest of the brain, with higher numbers of organisms seen being 
associated with higher pre-morbid CSF pressure [105]. Interestingly, a high fungal 
burden appears necessary but not sufficient for the development of high pressure 
[106]. Based on this understanding of mechanism, careful therapeutic lumbar 
punctures are recommended to control high pressure. The safe maximum volume of 
CSF to drain at one LP is unclear, but up to 30 ml are frequently removed in patients 
with high pressure, with checking of pressure after each 10 ml removed. Increasing 
evidence points convincingly to their efficacy. In the original data from the 1997 
MSG trial, high pressure was associated with increased acute mortality [104], whereas 
in a large cohort of patients in whom regular lumbar punctures were performed with 
additional therapeutic lumbar punctures if the pressure was high, there was no 
association of high baseline pressure with mortality. In fact, interestingly, the opposite 
trend was seen [55]. In addition, adherence to guidelines regarding CSF pressure 
measurement and management has been associated with improved outcome [107], 
and, in a Ugandan study, therapeutic LPs were associated with reduced mortality, 
irrespective of baseline pressure [108]. 
 
Importantly from a clinical standpoint, it is well recognised that high pressure, even if 
absent on presentation, may develop later, despite sterilization of CSF, typically in the 
second and third weeks [106]. Thus, it is vital that lumbar puncture is repeated and 
pressure measured in patients who fail to improve or in whom symptoms recur. 
Repeated daily therapeutic LPs are sufficient to control raised pressure in the majority 
of patients. Occasionally however, only a temporary lumbar drain, ideally managed 
on a neurosurgical facility, with which an order of magnitude more CSF per day can 
be safely drained, is sufficient [109, 110]. Our own and other’s experience suggests 
around 7 days temporary drainage is usually required (Figure 3)[110]. Ventricular 
shunts are also effective, but can usually be avoided in HIV-related CM.  
 
In contrast, a significant minority of non-HIV-infected individuals with CM have 
central obstruction of the choroid plexes within the foramen of Monroe or 
Luschka/Magendie with hydrocephalus or a superior arachoiditis and a 
communicating process of elevated pressures, both associated with robust 
inflammatory responses [70]. Thus, shunts are needed more often in non-HIV 
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associated meningitis because of hydrocephalus or persistent obstruction, and can be 
used safely provided antifungal therapy has been started [111]. 
 
Cryptococcal immune reconstitution inflammatory syndrome (CM-IRIS) 
 
CM-IRIS is a second common and life-threatening complication. In the context of 
HIV, there are 2 forms: paradoxical IRIS in patients who respond to initial antifungal 
therapy and then suffer a relapse of symptoms after starting ART; and unmasking 
cases who present for the first time after ART is started [112]. While reported rates of 
paradoxical IRIS vary as this remains a diagnosis of exclusion, dependent on how 
thoroughly alternative diagnoses can be investigated, it probably occurs in 10 to 20% 
of those surviving to start ART, at a median of 1-2 months after ART [113-115]. Risk 
factors include a low baseline CD4 cell count, with rapid subsequent rise, a low initial 
CSF white cell count, lower markers of inflammation and IFN- responses on initial 
presentation, and a high fungal burden, at baseline and day 14 [116-118]. In the 
principal component analysis of baseline CSF cytokine profiles by Jarvis et al, 
described above, PC-2, driven by high concentrations of chemokines, MCP-1 and 
MIP-1a, and of GM-CSF, were associated with the later development of IRIS [60] 
(Figure 1B), consistent with the findings of Chang et al [119]. These chemokines may 
enhance T and myeloid cell trafficking into the CNS, resulting, once restoration of 
CD4 Th1 subsets occurs following initiation of ART, in the excessive Th1-type 
immune responses seen during CM-IRIS episodes [51, 114, 120, 121] (Figure 4).  
 
As with other opportunistic infections, the question arises as to the best timing of 
ART, to avoid precipitating IRIS, while establishing HIV therapy as soon as possible. 
For cryptococcal disease, we know that within 3 days [122] and a median of 8 days 
[123] is too soon, and 6 weeks probably unnecessarily late [124]. In the COAT study 
[123], patients given early (at a median of 8 days) ART were found, as early as day 
14, to have higher CSF white cell counts and CSF markers of macrophage/microglial 
activation than patients not yet started on ART, suggesting the excess deaths in the 
early ART arm may have been immune mediated [125]. Thus, current guidelines 
suggest 4-6 weeks, although cohort evidence suggests starting patients during the 
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fourth week is safe in the context of rapidly fungicidal induction therapy [55], which 
should per se also help prevent IRIS.  
 
Patients who represent after the start of ART, should have an LP to check for ongoing 
active infection, and consideration of re-induction antifungal therapy (Table 2) 
pending culture results; and to measure and manage CSF pressure (high pressure 
again being an important feature of paradoxical CM-IRIS). Alternative diagnoses 
should be actively pursued. While CM-IRIS is clearly life-threatening, with 
awareness and early recognition, and short courses of corticosteroids for patients who 
are deteriorating, CM-IRIS-related mortality should be minimized [116]. In some 
cases, steroid weaning leads to recurrent IRIS, and case reports have described the use 
of thalidomide and adalimumab in refractory CM-IRIS in both HIV and transplant 
patients [126, 127].    
 
Unmasking HIV-associated CM-IRIS cases are characterised by lower organism loads 
compared with ART-naïve cases, and some, although not conclusive evidence, for 
increased inflammatory responses [128]. The balance between active infection and 
immune pathology may vary depending on the interval between ART start and 
presentation. If this is just a few days, there may be little difference from ART-naïve 
cases, while cases presenting much later, may be culture negative, and diagnosed on 
antigen testing only. Patients presenting with unmasking CM-IRIS are treated with 
the same antifungal regimens, although care is needed in view of interactions and 
overlapping side effects between antifungals and ART. Careful assessment is also 
needed to try to distinguish between unmasking cases, and the increasing number of 
patients who are ART-experienced but present with CM with persisting low CD4 cell 
counts due to non-adherence and/or ART resistance. In these latter cases, any 
switches or re-initiation of ART are best postponed until 4 weeks into antifungal 
therapy.   
 
Post-infectious Inflammatory Response Syndrome (PIIRS) in non-HIV patients 
 
In the non-HIV infected host, paradoxical immune reactions are a significant cause of 
clinical failure. In patients previously immunosuppressed with transplant conditioning 
or chemotherapy for haematological malignancies, reductions in immune suppressing 
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medications to boost the immune response frequently result in an IRIS-like 
reconstitution syndrome [102]. In previously healthy individuals where no immune 
reconstitution occurs, clinical deterioration commonly occurs during therapy not from 
microbiological failure but from an aggravated immune response, PIIRS. Primary 
differences in the non-HIV, compared with the HIV, setting include 
compartmentalization, with only intrathecal responses measurable, and an 
alternatively activated M2-like skewing of CNS-tissue infiltrating macrophages, 
which is a non-protective response in animal models [129]. As shown in Figure 4, 
PIIRS shares features with CM-IRIS including activation of the dendritic cell-T-cell 
synapse and T-cell inflammatory responses evidenced by elevated cytokines IFN- 
and IL-6. Biomarkers of this inflammatory process are the CSF soluble T-cell 
activation marker sCD27, which is associated with release of the axonal damage 
protein, neurofilament light chain, NFL. However, the syndrome differs from CM-
IRIS in that PIIRS lacks effective activation of macrophages, resulting in a 
“macrophage-T-cell dissociation,” resulting clinically with persistent tissue antigen 
and inflammation. As shown in Figure 5, corticosteroids have been useful in these 
patients with inflammatory brain lesions, whether infected with C. neoformans or C. 
gattii, once microbiological clearance is documented by negative CSF cultures [70, 
130].  
 
Prospects for immunotherapies 
 
As exemplified above, an increased understanding of the immunopathology in some 
non HIV cases, of immunological pre-dispositions to cryptococcal meningitis in the 
heterogeneous group of non HIV-infected CM patients, and of protective immune 
responses in patients with HIV-associated CM, should help to guide attempts to 
manipulate immune responses for patient benefit. Any such attempts will need to be 
host and situation specific, moving the damage-response framework [131] to an 
optimal balance of effective fungal clearance without immune pathology.  
 
Since PIIRS may be quite persistent in non-HIV CM due to macrophage clearance 
defects, and given the side effects of prolonged corticosteroid use, active research is 
currently directed at identifying steroid sparing immunosuppressants that are effective 
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in neuroinflammation. In non HIV-infected previously healthy patients, identification 
of genetic or immunological defects could be useful to guide attempts to augment 
microbiological control and to identify family members at risk. In addition, diseases 
such as pulmonary alveolar proteinosis are important co-morbidities to identify in 
non-HIV CM because pulmonary pathology may be problematic after resolution of 
meningitis and a number of therapies such as aerosolized GM-CSF have proven 
effective for pulmonary pathology [132, 133]. 
 
In HIV-associated CM, clinical trial data are consistent with the immune data from 
patients showing the importance of Th1-type immunity in controlling infection. In a 
large randomised trial, adjunctive steroids at the time of CM diagnosis were 
associated with a significantly increased risk of disability or death, increased adverse 
events, and a substantially reduced rate of fungal clearance [21]. In contrast, in two 
smaller trials, adjunctive IFN- appeared to be safe and augmented clearance without 
any indication of adverse effects on HIV viral control or IRIS [46, 134]. 
Unsurprisingly perhaps, the greatest effect was seen in patients with poor baseline 
Th1-type responses. Further studies are needed, and rapid assessment of immune 
status could enable targeting IFN- to those likely to benefit most. Even in HIV-
associated CM though, there are exceptions, in late unmasking cases, and those with 
paradoxical CM-IRIS, in whom immune pathology plays a significant role, and in 
whom such augmentation of immune responses should be avoided.  
 
Prevention  
 
Cryptococcal infection can be diagnosed through detection of cryptococcal 
polysaccharide antigen in blood, at a median in one study of 22 days prior to CNS 
symptoms developing [19], providing an opportunity for preventing the development 
of meningitis in very high-risk groups, such as those with late-stage HIV. In a 
retrospective study, Jarvis et al tested stored blood samples taken prior to initiation of 
ART from a cohort of over 700 prospectively monitored patients in Cape Town, 
South Africa [135]. None of 661 patients testing antigen negative (93% of the total), 
had gone on to develop CM in the first year of ART. In contrast, at least 7/25 (28%), 
of those testing antigen positive with no prior history of CM, had developed CM. This 
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100% negative predictive value supported the utility of antigen detection in a screen 
and pre-emptive therapy strategy, whereby patients at risk, with CD4 cell counts 
<100, would be tested for antigen and those testing positive given pre-emptive 
therapy with widely available and safe oral fluconazole. Several modelling studies 
suggested such a strategy would be highly cost-effective, saving lives and money, in 
light of the fact that the costs of admission and care of prevented cases would be 
avoided, even at very low prevalences of antigenaemia [136, 137]. On this basis, 
screening was endorsed in WHO guidelines [83], and programmes initiated in South 
Africa [138] and elsewhere, and by MSF.  
 
Some prospective data is now available that supports the strategy: in a randomised 
controlled trial in Tanzania and Zambia (REMSTART), screening, as described above 
of patients presenting for ART with a CD4 cell count <200, and simple lay-worker 
ART adherence support for the first month, led to a 28% reduction in overall 
mortality in the first year of ART [139]. Still, questions remain regarding how best to 
implement screening and in particular, over the best therapy for antigen positive 
patients. Data from REMSTART, and studies in Uganda and Cape Town all suggest 
that the mortality of antigen-positive patients remains significantly higher, at 25-30%, 
than that of those testing antigen negative, at around 10-12% [79, 139]; also, that a 
very significant proportion, around 40%, of antigen positive patients even if 
asymptomatic, are found, if they agree to LP, to have evidence of meningitis, defined 
by CSF antigenaemia [79]. Furthermore, higher blood antigen titres can predict those 
with meningitis [79], and are associated with poor outcome [Bozena et al CROI 
2016]. While fluconazole may be enough for many antigen positive patients, patients 
with evidence of meningitis may need more aggressive antifungal therapy, and a 
follow up trial is planned that will compare fluconazole with fluconazole plus 
flucytosine for those testing antigen positive. New semi-quantitative antigen tests may 
be able to rapidly identify those who would benefit from more intensive treatment. 
 
Conclusions 
 
Cryptococcal meningitis is a leading fungal cause of human disease and death 
worldwide. However, expanding access to current antifungal drugs [140], and 
optimising their use in regimens that are sustainable in resource-limited settings, 
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together with earlier diagnosis, enabled by a new point-of-care immunodiagnostic 
test, and therapeutic lumbar punctures to manage the common complication of raised 
cerebrospinal fluid pressure, have the potential to significantly reduce the global 
disease burden. Drug discovery aimed specifically at Cryptococcus species is limited, 
but one promising new agent, Viamet-1129, is now entering clinical evaluation. 
Immunomodulatory adjunctive therapies hold promise, but need to be carefully 
tailored to the patient and clinical scenario, based on advances in our understanding 
host immunity in different patient populations. 
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BOX: Ecology, evolution and virulence of Cryptococcus  
 
Cryptococcus is a genus within the Tremellales, an order of fungi that are 
commonly found growing on rotting wood as saprophytes and called ‘jelly fungi’ 
due to their gelatinous fruiting bodies. There are over 30 recognised species of 
Cryptococcus of which two, C. neoformans and C. gattii, cause the majority of 
human infections. Both species are readily recovered from the environment where 
they can be isolated from the bark of a wide variety of tree species and other 
organic matter, notably bird faeces. Cryptococcus are therefore members of a 
growing class of pathogens, sapronoses [1], that are accidental parasites on 
primarily immunocompromised individuals, and which gain no evolutionary 
advantage from infecting the human host [2]. The virulence of Cryptococcus 
therefore most likely owes to adaptations that allow it to survive in the 
environment [7]. An array of recognised ‘dual-use’ virulence factors are known 
[8], including a thick polysaccharide capsule [11] which, in the environment 
defends against parasitic amoeba, however in the human allows the fungus to 
survive as macrophages assault and to disseminate as an intracellular parasite. 
Genetic analysis has shown that C. neoformans and C. gattii have had independent 
evolutionary histories for an estimated 30-40 million years [13]. This separation 
has resulted in subtle variation in their virulence with C. neoformans being the 
predominating infection in immunocompromised HIV/AIDS individuals compared 
to C. gattii which is a rarer infection and associated with putatively 
immunocompetent individuals. Both species are highly diverse and contain within 
them a number of phylogenetically distinct lineages that likely represent cryptic 
species; the two species are currently undergoing taxonomic revision into 
potentially seven species [15].  Genomic analysis of C. gattii has described four 
main major lineages (VGI-VGIV) [16] with population genetic analyses 
suggesting a center of origin of the hypervirulent VGII lineage in South America 
[17]. C. neoformans is similarly diverse, with two recognised cryptic species each 
containing evolutionary distinct lineages; C. neoformans var. grubii (lineages VNI, 
VNII, VNB) which appears to have a center of diversity in Africa, and C. 
neoformans var. neoformans (lineage VNIV). Both C. gattii and C. neoformans 
are facultatively sexual with a bipolar mating system, and hybrids can form both 
between species and lineages.  
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Table 1 
Summary of data re genetic pre-disposition in non HIV CM 
 
Syndromes, Autoantibodies Reference 
Idiopathic CD4 lymphopenia 
Pulmonary alveolar proteinosis, autoantibodies to GMCSF 
and IFN-   
27,28 
29-31 
32 
Monogenic Disorders  
GATA2 
CGD 
Job’s syndrome 
X-linked CD40L deficiency (hyper IgM syndrome) 
33-35 
 
36,37 
38,39 
Polygenetic modifiers  
FCg receptor II 40 
Co-morbidities  
Sarcoidosis, autoimmune disease, steroid treatment  
Hepatic disease 
Solid organ transplant conditioning 
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Table 2: Antifungal therapy 
 
Induction therapy Duration 
L-AmB 3-6 mg/kg/day or D-AmB 0.7–1.0 mg/kg/day; 
plus 5-FC 100 mg/kg/day (75 mg/kg/day if intravenous 
formulation used) 
L-AmB preferred in transplant patients; and when induction 
for >2 weeks  
2 weeks (HIV-CM) 
>2 weeks (transplant-
CM)* 
4-6 weeks (non-HIV 
non transplant, 
including C. gatti)* 
Consolidation  
Fluconazole 400-800 mg/day** 8 weeks 
Maintenance therapy  
Fluconazole 200 mg/day, in HIV-CM start ART at 4 weeks. 
Consider discontinuing maintenance after a minimum of 1 
year if CD4+ cell count >100 /L and HIV viral load 
suppressed 
 
1 year 
Induction therapy in resource limited settings  
If 5-FC is not available: D-AmB 0.7–1 mg/kg/day 
intravenously plus fluconazole 800-1200 mg/day 
2 weeks (1 week 
better than no D-
AmB) 
If D-AmB is not available: Fluconazole 1200 mg/day†  
plus flucytosine 100 mg/kg/day orally (if available) 
2 weeks 
 
HIV-CM: HIV-associated cryptococcal meningitis; L-AmB: Liposomal amphotericin B; D-AmB: 
amphotericin B deoxycholate; 5-FC: flucytosine; ART: antiretroviral therapy. 
* see IDSA guidelines [84] 
** 800 mg/d preferred if second line induction regimens used 
†Fluconazole increases nevirapine levels, and safety of high-dose fluconazole with nevirapine is 
unknown. Alternative antiretrovirals are preferred.  
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Figure legends 
 
Figure 1 
Associations between baseline cerebrospinal fluid immune response profiles and 
clinical outcome. Baseline CSF cytokine and chemokine concentrations were 
measured in 90 patients with HIV-associated cryptococcal meningitis. Principal 
component analysis was used to identify co-correlated cytokine and chemokine 
measurements that accounted for the variance across the data set. A majority of this 
variance was accounted by two components, PC1 and PC2 (see text). A. PC1 score 
was associated with 2 week survival. B. In those who survived and were started on 
ART, PC2 score was associated with the development of CM-IRIS. The points 
represent the mean values, with standard errors denoted by the error bars. From Jarvis 
et al [60] 
 
Figure 2 
Differences in functional phenotype of the cryptococcal antigen (CRAG)–specific 
responses at baseline between subjects who survived and subjects who died. Flow 
cytometry results show the proportion of cryptococcal antigen (mannoprotein 
fraction) -specific CD4 positive memory T cells producing interferon γ (IFN-γ), 
interleukin 2 (IL-2), macrophage inflammatory protein 1α (MIP-1α), tumor necrosis 
factor α (TNF-α), and combinations of these cytokines, at baseline, for patients who 
survived to 2 weeks and those who died. From Jarvis et al [59]. 
 
Figure 3. Raised CSF pressure. Time course of CSF pressure, visual acuity, and 
volume of CSF drained through a temporary lumbar drain in situ for 11 days, in a 
patient developing severely raised pressure, unresponsive to repeated daily lumbar 
punctures, during the third week of antifungal therapy, despite sterilization of CSF.                  
 Indicates time of lumbar puncture. From Macsween et al [109]. 
 
Figure 4 
Host damage from infection-related inflammatory syndromes. CM patients with 
immune reconstitution syndrome (HIV-IRIS) after effective anti-retroviral therapy 
present with clinical deterioration with negative CSF cultures, but an aggravated T-
cell and pro-inflammatory macrophage response (top panel). Previously healthy 
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patients with CM having clinical deterioration on effective therapy develop a similar 
post-infectious immune response syndrome (PIIRS) consisting of a similar T-cell 
response but a defective M2 macrophage polarization that is ineffective in clearing 
fungal antigen. From Panackal et al [51]. 
 
Figure 5 
Magnetic resonance imaging demonstrating reductions in brain edema after treatment 
with corticosteroid therapy. T1 and FLAIR-weighted Magnetic resonance images of a 
patient with C. gattii infection and anti-GMCSF autoantibody treated with 
Amphotericin B from day 1-66 + adjunctive prednisone (50 mg/d) between day 1 and 
day 24. Therapy was then stopped on day 24 but then re-instituted at days 34-66 after 
clinical deterioration. (Figure from Panackal et al [70]) 
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Figure 3: 
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